There is no effective drug targeting AQP4 that has been directly approved for clinical use, although AQP4 has been proven to have therapeutic potential in stroke, traumatic brain injury, and other neurodegenerative diseases [151,152,153]. This evidence concerns the gene AQP4 and neurodegenerative disease.